208Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Belgium
Neuroscience Intelligence
Belgium neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #12 of 50 · Data maturity A · Research score 41.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
43Recruiting trials
193Publications
87Institutions
Executive interpretation
Belgium ranks #12 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
University Hospital, Ghent110 recruiting
Hoffmann-La Roche112 recruiting
Merck Sharp & Dohme LLC117 recruiting
Novartis Pharmaceuticals72 recruiting
KU Leuven60 recruiting
Université Catholique de Louvain60 recruiting
Cliniques universitaires Saint-Luc- Université Catholique de Louvain62 recruiting
Janssen Research & Development, LLC50 recruiting
Biogen51 recruiting
UCB Pharma50 recruiting
Disease activity
Epilepsy33trials
Alzheimers33trials
Parkinsons24trials
Stroke23trials
Neuromuscular15trials
Multiple Sclerosis14trials
Other Neurology13trials
Pain Neuropathy8trials
Autism6trials
Adhd6trials
Research institutions
Damiaan Dicht bij het levenOpenAlexlinked institution
UCLouvain Saint-Louis BrusselsOpenAlexlinked institution
Ludwig Cancer ResearchOpenAlexlinked institution
Thomas More KempenOpenAlexlinked institution
AZ Maria MiddelaresOpenAlexlinked institution
Onze Lieve Vrouwziekenhuis HospitalOpenAlexlinked institution
European Heart NetworkOpenAlexlinked institution
International Life Sciences Institute EuropeOpenAlexlinked institution
Fujirebio (Belgium)OpenAlexlinked institution
AZ KlinaOpenAlexlinked institution
Clinical evidence trail
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseACTIVE_NOT_RECRUITING
NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDAlzheimer's disease-associated presenilin 2 N141I mutation impairs neuronal lipid homeostasis and mitochondrial dynamics through selective downregulation of the Golgi exchange factor Gbf1.2027-01-01
PUBMEDDeconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.2026-12-31
PUBMEDSubjective and objective memory effects after electroconvulsive therapy for depressive disorders - systematic review and meta-analysis.2026-12-01
PUBMEDImputation benchmarking in clinical databases: constraint enforcement for bounded neuropsychological assessments.2026-12-01
PUBMEDBrain-motor behavior coupling during walking while negotiating obstacle: A systematic review.2026-12-01
PUBMEDCurrent practice, clinical perspectives and barriers to multi-night testing for obstructive sleep apnea in Europe: a survey across ESADA centers.2026-12-01
PUBMEDNovelty seeking and rapid symptom improvement across active and sham accelerated iTBS conditions: A pooled individual-patient data analysis.2026-12-01
PUBMEDAssociation of depression and epilepsy in rural northern Rwanda: a prospective longitudinal study with a patient-centered approach.2026-12-01
PUBMEDEBNA1381-452 and Cross-Reactive Antibody Responses Reveal Immune Signatures in Multiple Sclerosis.2026-11-01
PUBMEDPhenotype-driven response to sodium channel blockers in neonatal and infantile genetic epilepsies with tonic seizures.2026-11-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.